Results 71 to 80 of about 1,941 (170)
A guide to transcriptional cyclin‐dependent kinases in cancer
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Abstract Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...
Philip Choi +9 more
wiley +1 more source
Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran +2 more
wiley +1 more source
Management of chronic urticaria: Current status and future prospect
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman +15 more
wiley +1 more source
Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley +1 more source
Ингибиторы тирозинкиназы Брутона (BTK) коренным образом изменили подходы к лечению B-клеточных хронических лимфопролиферативных заболеваний (ЛПЗ), существенно улучшив показатели выживаемости и качество жизни пациентов.
Юлия Сергеевна Ефремова +2 more
doaj +1 more source
Abstract This article examines the 1921–1923 trade war between Norway and Portugal as a historical case for exploring business responses to deglobalization and trade disruption. Focusing on the international supply chains (ISCs) of port wine and salted and dried cod, it investigates how business actors contributed to the recoupling of ISCs after a ...
Rolv Petter Amdam +3 more
wiley +1 more source
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford +32 more
wiley +1 more source
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin +92 more
wiley +1 more source

